scholarly journals Clinical outcomes associated with proton pump inhibitor use among clopidogrel-treated patients within CYP2C19 genotype groups following acute myocardial infarction

2014 ◽  
Vol 15 (1) ◽  
pp. 20-25 ◽  
Author(s):  
J P Depta ◽  
P A Lenzini ◽  
D E Lanfear ◽  
T Y Wang ◽  
J A Spertus ◽  
...  
Keyword(s):  
Myocardial Infarction ◽  
Acute Myocardial Infarction ◽  
Proton Pump Inhibitor ◽  
Clinical Outcomes ◽  
Proton Pump ◽  
Cyp2c19 Genotype

scholarly journals Association of proton pump inhibitor use with disease burden and cardiometabolic profile among patients hospitalized for acute myocardial infarction

2021 ◽  
Vol 16 (1-2) ◽  
pp. 5-5
Author(s):  
Admira Bilalić ◽  
Josip Anđelo Borovac ◽  
Tina Tičinović Kurir ◽  
Marko Kumrić ◽  
Andrija Matetić ◽  
...  
Keyword(s):  
Myocardial Infarction ◽  
Acute Myocardial Infarction ◽  
Proton Pump Inhibitor ◽  
Proton Pump ◽  
Disease Burden ◽  
Cardiometabolic Profile

Proton Pump Inhibitor Exposure and Acute Myocardial Infarction Risk: A Nested Cohort Study

2021 ◽  
Author(s):  
Hsiang-Jung Tseng ◽  
Chih-Ming Cheng ◽  
Shih-Jen Tsai ◽  
Wei-Chen Lin ◽  
Ya-Mei Bai ◽  
...  
Keyword(s):  
Myocardial Infarction ◽  
Acute Myocardial Infarction ◽  
Cohort Study ◽  
Proton Pump Inhibitor ◽  
Proton Pump

scholarly journals Effects of stent generation on clinical outcomes after acute myocardial infarction compared between prediabetes and diabetes patients

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Yong Hoon Kim ◽  
Ae-Young Her ◽  
Myung Ho Jeong ◽  
Byeong-Keuk Kim ◽  
Sung-Jin Hong ◽  
...  
Keyword(s):  
Myocardial Infarction ◽  
Acute Myocardial Infarction ◽  
Clinical Outcomes ◽  
Secondary Outcome ◽  
Drug Eluting Stent ◽  
Diabetes Group ◽  
Repeat Revascularization ◽  
Group A ◽  
Group B ◽  
Diabetes Patients

AbstractWe investigated the effects of stent generation on 2-year clinical outcomes between prediabetes and diabetes patients after acute myocardial infarction (AMI). A total of 13,895 AMI patients were classified into normoglycemia (group A: 3673), prediabetes (group B: 5205), and diabetes (group C: 5017). Thereafter, all three groups were further divided into first-generation (1G)-drug-eluting stent (DES) and second-generation (2G)-DES groups. Patient-oriented composite outcomes (POCOs) defined as all-cause death, recurrent myocardial infarction (Re-MI), and any repeat revascularization were the primary outcome. Stent thrombosis (ST) was the secondary outcome. In both prediabetes and diabetes groups, the cumulative incidences of POCOs, any repeat revascularization, and ST were higher in the 1G-DES than that in the 2G-DES. In the diabetes group, all-cause death and cardiac death rates were higher in the 1G-DES than that in the 2G-DES. In both stent generations, the cumulative incidence of POCOs was similar between the prediabetes and diabetes groups. However, in the 2G-DES group, the cumulative incidences of Re-MI and all-cause death or MI were significantly higher in the diabetes group than that in the prediabetes group. To conclude, 2G-DES was more effective than 1G-DES in reducing the primary and secondary outcomes for both prediabetes and diabetes groups.

Sign in / Sign up

Export Citation Format

Share Document